34 Teachers and Schools Across North America Receive $10,000 Amgen Award

AmgenAmgen (Nasdaq: AMGN) announced the 34 science teachers in the United States (U.S.), Canada and Puerto Rico who are this year's recipients of the 18th annual Amgen Award for Science Teaching Excellence. The award recognizes extraordinary teachers in grades K-12 whose dedication to students has had a significant impact on the learning and interest of the future generation of scientists.

Since the program's inception in 1992, Amgen has awarded more than $2.5 million to educators who have made exceptional science-teaching contributions and who have achieved demonstrated results in student learning in communities where Amgen operates. In 2010, Amgen received nearly 250 applications for the Amgen Award for Science Teaching Excellence and winners were honored at special ceremonies in their respective Amgen communities or during surprise presentations at their schools.

"Amgen believes in the enduring value of science education and is committed to supporting programs that encourage bright young minds to explore a future in science," said Joe Miletich, senior vice president of research and development at Amgen. "We applaud this year's award recipients for their dedication to delivering quality science education to tomorrow's innovators."

The 34 selected winners will receive the following benefits:

  • An unrestricted cash award of $5,000 USD or $5,000 CAD; and
  • A restricted $5,000 USD or $5,000 CAD cash grant to the recipient's school for the expansion or enhancement of a school science program, science resources, or the professional development of the school's science teachers;

Along with the award applications, teachers were asked to submit an innovative science lesson plan which had been successfully introduced in their classroom. Amgen will post select winning lesson plans to its Web site to promote the sharing of this knowledge with educators across the country to bolster excellence and innovation in science teaching.

Amgen partnered with the University of Wisconsin - Madison School of Education to judge the teaching awards in the U.S. and Puerto Rico. The School's Department of Curriculum and Instruction is consistently recognized as a leader in education, and their expertise aided in the selection of the strongest possible winners.

Nominations are solicited every fall with winners selected based on the following criteria: innovative science lesson plan, creativity and effectiveness of teaching methods; and the plan for the use of grant money to improve science education resources in their schools.

For more information about this year's winners and the program, please visit http://www.amgen.com/citizenship/aaste.html.

About Amgen
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.

Most Popular Now

Novo Nordisk announces plans to transform its appr…

Novo Nordisk announced plans to restructure its Research & Development (R&D) organisation to accelerate the expansion and diversification of its pipeline across serious c...

The Merck Accelerator Program 2019

The Merck Accelerator is looking for real partners so that you can work together in shaping the future. With programs in the headquarters in Germany, in China and the Sat...

World's largest Alzheimer's survey reveals most ad…

Amgen (NASDAQ:AMGN), Novartis and Banner Alzheimer's Institute (BAI), in association with Alzheimer's Disease International (ADI), announced results from the largest glob...

Imfinzi is the first immunotherapy to demonstrate …

AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of Imfinzi durin...

Pre-clinical success for a universal flu vaccine o…

Researchers from the University of Oxford's Department of Zoology have demonstrated pre-clinical success for a universal flu vaccine in a new paper published in Nature Co...

Discovery could explain failed clinical trials for…

Researchers at King's College London have discovered a vicious feedback loop underlying brain degeneration in Alzheimer's disease which may explain why so many drug trial...

Global survey reveals that physicians need more in…

Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make inf...

Aspirin found not to prolong healthy aging

Taking a low-dose aspirin daily does not prolong healthy living in older adults, according to findings from the ASPirin in Reducing Events in the Elderly (ASPREE) trial p...

The Lancet Respiratory Medicine publishes first Ph…

AstraZeneca today announced publication of results from the KRONOS Phase III trial which evaluated the efficacy and safety of triple combination therapy PT010 (budesonide...

In clinical trials, new antibody therapy controls …

Thanks to improvements in antiretroviral therapy, HIV is now a manageable condition. Yet even the best drugs do not entirely eliminate the virus, which latently lingers i...

FDA approves first treatment for advanced form of …

The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squam...

Clinical gene discovery program solves 30 medical …

A table in a recently published paper tells the story of 30 families who have, sometimes after years of searching, finally received an answer about the condition that has...